We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

76 hedge funds and large institutions have $397M invested in Krystal Biotech in 2019 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

173% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 11

86% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 14

78% more capital invested

Capital invested by funds: $223M → $397M (+$174M)

33% more funds holding

Funds holding: 57 → 76 (+19)

11.48% more ownership

Funds ownership: 46.53% → 58.01% (+11%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
76
Holders Change
+19
Holders Change %
+33.33%
% of All Funds
1.65%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
30
Increased
26
Reduced
14
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$24.7M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$20.4M
3
O
OrbiMed
New York
+$19.1M
4
BlackRock
BlackRock
New York
+$17.9M
5
BBA
Baker Bros. Advisors
New York
+$8.17M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$16.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.85M
3
SFM
Sphera Funds Management
Israel
-$2.09M
4
KCM
Knoll Capital Management
Florida
-$2.06M
5
ECM
Endurant Capital Management
California
-$2.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$46.2M -$2.85M -87,114 -7%
RG
2
Redmile Group
California
$43.5M +$24.7M +755,800 +233%
BBA
3
Baker Bros. Advisors
New York
$41.7M +$8.17M +250,000 +32%
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$37.3M +$20.4M +622,959 +205%
FM
5
Frazier Management
Washington
$36M +$654K +20,000 +2%
O
6
OrbiMed
New York
$25.9M +$19.1M +582,796 +984%
BlackRock
7
BlackRock
New York
$24.2M +$17.9M +546,317 +990%
Citadel Advisors
8
Citadel Advisors
Florida
$20M +$5.7M +174,296 +54%
Vanguard Group
9
Vanguard Group
Pennsylvania
$20M +$4.69M +143,409 +41%
AG
10
Artal Group
Luxembourg
$12.1M – – –
CCM
11
Consonance Capital Management
New York
$7.33M +$5.95M +182,090 New
State Street
12
State Street
Massachusetts
$6.37M +$4.94M +151,143 +2,158%
KCM
13
Knoll Capital Management
Florida
$5.92M -$2.06M -62,896 -30%
Millennium Management
14
Millennium Management
New York
$4.83M +$1.01M +30,774 +35%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$4.82M +$1.57M +48,069 +67%
SFM
16
Sphera Funds Management
Israel
$4.74M -$2.09M -64,000 -35%
NIP
17
Nicholas Investment Partners
California
$4.44M -$32.6K -996 -0.9%
Carson Wealth (CWM LLC)
18
Carson Wealth (CWM LLC)
Nebraska
$4.22M – – –
Point72 Asset Management
19
Point72 Asset Management
Connecticut
$4.09M +$576K +17,616 +21%
EI
20
EAM Investors
California
$3.28M +$1.92M +58,626 +257%
CS
21
Credit Suisse
Switzerland
$2.79M +$2.26M +69,212 New
SST
22
S Squared Technology
New York
$2.72M -$44.7K -1,367 -2%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$2.61M +$1.43M +43,859 +210%
Verition Fund Management
24
Verition Fund Management
Connecticut
$2.52M +$2.05M +62,650 New
GECH
25
Garnet Equity Capital Holdings
New York
$1.81M +$1.47M +45,000 New
1
2 3 4

KRYS Hedge Fund Activity: Q2 2019 in Review

76 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q2 2019, worth a combined $397M — up 78% from $223M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new KRYS positions and 11 closed out — a net gain of 19 holders — while 26 added to existing stakes and 14 trimmed.

The largest buyer was Redmile Group, adding an estimated $24.7M. The largest seller was Great Point Partners, exiting entirely with an estimated $16.2M sold.

  • 76 institutional investors held Krystal Biotech (KRYS) as of Q2 2019, up from 57 in Q1 2019.
  • Funds reported $397M of Krystal Biotech stock for Q2 2019, up 78% quarter-over-quarter.
  • 30 funds opened new Krystal Biotech positions in Q2 2019 and 11 closed out, a net change of +19 holders.
  • The largest Krystal Biotech buyer in Q2 2019 was Redmile Group, an estimated $24.7M added.
  • The largest Krystal Biotech seller in Q2 2019 was Great Point Partners, an estimated $16.2M sold.

Based on aggregated 13F filings for Q2 2019.